HCPToday’s Post

Nice proof of concept study for a potential drug interfering with the optimal target point regarding Amyloid beta in Alzheimer’s disease , i.e. avoiding Amyloid beta dysfunction.

Today is World Multiple Sclerosis (MS) Day, and we're highlighting this challenging disease that affects millions. Our latest blog by Nicholas Woudberg explores how understanding integrins has led to breakthroughs in MS treatment, significantly reducing relapses and improving patient outcomes. We also discuss the exciting advancements in MS therapies, making treatments more accessible and affordable. Read our blog to learn more about the progress in MS treatment: https://lnkd.in/dvvvGy_2 #Synea #lifesciences #ms #multiplesclerosis

Abnormal B-Cells and Tfh-Cell Profiles in patients with Parkinsons IL-10–producing B-cell counts are reduced in patients with Parkinson disease (PD) (A), whereas GM-CSF and TNFα-expressing B-cell frequencies are increased in patients with PD (B), which together results in decreases of both GM-CSF/IL-10 ratios (C) and TNFα/IL-10 ratios (D) ratios of cytokine-expressing B cells in PD

Acetylcholinesterase inhibitors are frequently used in the treatment of Alzheimer disease due to their anti-inflammatory effects. But what is the potential of this class of medications to also impact the risk of age-related macular degeneration in this patient population? Joseph Magagnoli, MS, discusses the results of his team's study, as well as the relationship between AD and AMD and remaining gaps in the literature, in this Q&A. Click here to read the full article: https://okt.to/O4f5HV

A single dose of lisocabtagene maraleucel led to rapid responses in patients with relapsed or refractory CLL/SLL. #TANDEM24 | ASTCT https://lnkd.in/eN6ZCCwq

Compared with HCTZ, chlorthalidone better decreases risk for MACEs and noncancer death in patient with hypertension and history of MI or stroke. https://brnw.ch/21wLEiC

"We discuss the potential relevance of molecular remission in VEXAS syndrome and highlight the importance of a multidisciplinary team for the care of such complex patients."

🗞 In case you missed it... Yesterday, Minoryx Therapeutics shared positive results from a compassionate use study of #leriglitazone* for the treatment of progressive #cALD - a rare, fatal neurodegenerative disorder affecting the brain. 📰 Read more about it with the official release, linked via the post below. 🔬 Read the full study here: https://bit.ly/3KGp7ow 📽 Watch the video summary of the study, here: https://bit.ly/3XeStlh *Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases.

Exciting news in glaucoma care! Recent studies show promising results for a new neuroprotective therapy. This could be a game-changer for preserving vision in our patients. What are your thoughts on this development? #GlaucomaCare #MedicalInnovation "Perfuse Therapeutics’ primary focus is endothelin signaling, implicated in a variety of diseases. Endothelin signaling is a key regulator of blood vessel tone. Endothelin is the strongest vasoconstrictor in the human body, and excess levels result in decreased blood flow and cell damage. In addition to its key role in regulating blood vessel tone, endothelin plays a role in regulating inflammation and cell death through its receptors expressed in vascular and non-vascular cells." https://lnkd.in/e9zkCUNm

Can we spare local treatment for brain mets in patients where osimertinib is being used ? Local treatment plus osimertinib better than using osimertinib alone #osimertinib #lungcancer #lungcanertreatment